Completed PHASE3 INTERVENTIONAL 1-arm NCT01789957

Extension Study for 2993-112

An Open-Label Extension Study of Protocol 2993-112 to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated With Metformin Alone

Sponsor: AstraZeneca

Conditions Type 2 Diabetes Mellitus

Interventions AC2993

Updated 7 times since 2017 Last updated: Feb 23, 2015 Started: Sep 30, 2002 Primary completion: Jun 30, 2004 Completion: Jun 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alcoa, United States , Anaheim, United States , Ann Arbor, United States , Anniston, United States , Arlington, United States , Atherton, United States , Atlanta, United States , Austin, United States , Bakersfield, United States and 156 more locations